PMID- 9831134
OWN - NLM
STAT- MEDLINE
DCOM- 19990205
LR  - 20190905
IS  - 0198-8859 (Print)
IS  - 0198-8859 (Linking)
VI  - 59
IP  - 12
DP  - 1998 Dec
TI  - Binding specificity of a class II-restricted hepatitis B epitope by DR molecules 
      from responder and nonresponder vaccine recipients.
PG  - 783-93
AB  - A small but significant proportion of people who receive the hepatitis B vaccine 
      do not produce anti-hepatitis B antibodies, a phenomenon associated with certain 
      human leukocyte antigen (HLA) class II haplotypes. We were interested in 
      determining whether natural allelic differences between two HLA-DR4 molecules 
      associated with responder versus nonresponder subtypes differed with respect to 
      binding of an immunodominant hepatitis B surface antigen (HBsAg) peptide as 
      measured using a resonant mirror biosensor. In contrast to our original 
      hypothesis, we found a ten-fold difference in the affinity in favor of the 
      nonresponder DRB1*0401 allele, with a KD of 6.89 x 10(-8) M versus a KD of 6.71 x 
      10(-7) M for the responder DRB1*0404 allele. Half-times of dissociation were 1.3 
      min and 7.7 min, respectively, although association rate constants for both HLA 
      class II molecules were similar (approximately 10(4) M(-1)s(-1)). Of particular 
      interest was the observation of different on-rates during the association phase, 
      suggesting that stoichiometry of binding was not 1:1 or that different structural 
      forms of the HLA-peptide complex exist. Our observations indicate that whereas 
      HBsAg peptide binding to HLA class II molecules is influenced by HLA 
      polymorphism, the nonresponse to hepatitis B vaccine associated with this HLA-DR4 
      subtype is not a result of failure of processed HBsAg to bind HLA class II 
      molecules.
FAU - Schuenke, K W
AU  - Schuenke KW
AD  - Department of Microbiology and Immunology, Baylor College of Medicine, Houston, 
      Texas 77030, USA.
FAU - Cook, R G
AU  - Cook RG
FAU - Rich, R R
AU  - Rich RR
LA  - eng
GR  - R37 AI15394/AI/NIAID NIH HHS/United States
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Hum Immunol
JT  - Human immunology
JID - 8010936
RN  - 0 (HLA-DR Antigens)
RN  - 0 (HLA-DR4 Antigen)
RN  - 0 (Hepatitis B Antibodies)
RN  - 0 (Hepatitis B Surface Antigens)
RN  - 0 (Hepatitis B Vaccines)
RN  - 0 (Histocompatibility Antigens Class II)
RN  - 0 (Immunodominant Epitopes)
RN  - 0 (Peptides)
RN  - 0 (Receptors, Antigen, T-Cell)
SB  - IM
MH  - Alleles
MH  - Biosensing Techniques
MH  - Cloning, Molecular
MH  - Enzyme-Linked Immunosorbent Assay
MH  - HLA-DR Antigens/immunology/*metabolism
MH  - HLA-DR4 Antigen/genetics/metabolism
MH  - Hepatitis B/*immunology/prevention & control
MH  - Hepatitis B Antibodies/blood
MH  - Hepatitis B Surface Antigens/immunology/*metabolism
MH  - Hepatitis B Vaccines/administration & dosage/*immunology
MH  - Histocompatibility Antigens Class II/genetics/isolation & purification
MH  - Histocompatibility Testing
MH  - Humans
MH  - Immunodominant Epitopes/*immunology/metabolism
MH  - Kinetics
MH  - Peptides/immunology/metabolism
MH  - Receptors, Antigen, T-Cell/immunology/metabolism
MH  - T-Lymphocytes/immunology
EDAT- 1998/11/27 00:00
MHDA- 1998/11/27 00:01
CRDT- 1998/11/27 00:00
PHST- 1998/11/27 00:00 [pubmed]
PHST- 1998/11/27 00:01 [medline]
PHST- 1998/11/27 00:00 [entrez]
AID - S0198-8859(98)00072-X [pii]
AID - 10.1016/s0198-8859(98)00072-x [doi]
PST - ppublish
SO  - Hum Immunol. 1998 Dec;59(12):783-93. doi: 10.1016/s0198-8859(98)00072-x.